help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Silha, J. V.
Right arrow Articles by Murphy, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Silha, J. V.
Right arrow Articles by Murphy, L. J.
Endocrinology Vol. 142, No. 10 4305-4313
Copyright © 2001 by The Endocrine Society


ARTICLES

Overexpression of the Acid-Labile Subunit of the IGF Ternary Complex in Transgenic Mice

Josef V. Silha, Yaoting Gui, Tomislav Modric1, Adisak Suwanichkul, Susan K. Durham, David R. Powell and Liam J. Murphy2

Departments of Internal Medicine (L.J.M.) and Physiology (J.V.S., Y.G., T.M., L.J.M.), University of Manitoba, Winnipeg, Manitoba, Canada R3E 0W3; and Department of Pediatrics, Baylor College of Medicine (A.S., S.K.D., D.R.P.), Houston, Texas 77030

Address all correspondence and requests for reprints to: L. J. Murphy, M.B., Ph.D., Departments of Internal Medicine and Physiology, University of Manitoba, Winnipeg, Manitoba, Canada R3E 0W3. E-mail: ljmurph{at}cc.umanitoba.ca


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The ternary complex, composed of IGF-I or IGF-II, IGF-binding protein-3, and the acid-labile subunit, is responsible for transport of the majority of the IGF-I and IGF-II present in the circulation. Acid-labile subunit is developmentally and hormonally regulated, suggesting an important, although unclear, role in regulating the availability and action of the IGFs. To investigate the biological role of acid-labile subunit, we generated transgenic mice, which constitutively overexpress a human acid-labile subunit cDNA driven by the cytomegalovirus promoter. Two independent transgenic strains, CMVALS-1 and CMVALS-2, with mean serum levels of human acid-labile subunit of 19.3 ± 4.2 and 20.2 ± 3.2 µg/ml respectively, were characterized. Total acid-labile subunit, endogenous plus transgene derived, was measured by Western blotting and was found to be significantly increased in transgenic compared with wild-type mice (1.51 ± 0.02-fold; P < 0.001). There were no significant differences in serum IGF-binding protein-3 or IGF-I levels between transgenic and wild-type mice. Similar chromatographic elution patterns were observed when sera from transgenic and wild-type mice were preincubated with [125I]IGF-I, indicating that acid-labile subunit overexpression had no measurable effect on compartmentalization of IGF-I in the circulation. Transgene-derived human acid-labile subunit mRNA was detected in 17-d-old embryos and all adult mouse tissues examined.

A significant reduction in litter size was also observed in each of the acid-labile subunit transgenic mouse strains. This reduction in litter size was due to a maternal effect, as it was apparent when transgenic female mice were crossed with wild-type male mice, but not when male transgenic mice were crossed with female wild-type mice.

The transgenic mice were phenotypically normal at birth, but demonstrated a significant reduction in postnatal body weight gain, particularly during the first 3 wk of life. Over the first 3 months of life, average body weights were significantly reduced by 5.3 ± 0.6%, 4.2 ± 0.6%, 8.1 ± 0.9%, and 5.6 ± 0.8%, compared with those in wild-type mice, for male and female CMVALS-1 mice and male and female CMVALS-2 mice, respectively. Double transgenic mice, generated by crossing acid-labile subunit transgenic mice with transgenic mice that overexpress IGF-binding protein-3, demonstrated a significantly more marked reduction in body weight gain than acid-labile subunit transgenic mice.

These data demonstrate that overexpression of acid-labile subunit has significant effects on postnatal growth and reproduction. As there is little measurable alteration in the circulating components of the IGF system, these effects are most likely to be mediated via disturbances in tissue IGF availability.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
IGF-I AND IGF-II are present in plasma and most biological fluids as a complex with IGF-binding proteins (IGFBPs). Of the six IGFBPs identified to date, IGFBP-3 is the most abundant in plasma (1). IGFBP-3 and the lesser abundant, but structurally similar, binding protein, IGFBP-5, can form complexes with a variety of other plasma proteins (2, 3, 4, 5). In plasma, the majority of IGFBP-3 is present as a ternary complex, consisting of IGFBP-3 together with IGF-I or IGF-II and an 85-kDa acid-labile protein, the acid-labile subunit (ALS) (1, 6). Complexes consisting of only IGFBP-3 and ALS have also been described (7).

Unlike binary complexes of IGFBP-3 and IGF-I or IGF-II, which can egress from the circulation across the endothelium, ternary complexes appear to be restricted to the circulation (8). The appearance of the ternary complex in the circulation shortly after birth is believed to serve as a relatively stable reservoir of circulating IGFs. However, it is not clear what physiological function this reservoir serves or how IGFs are liberated from the ternary complex to exert their biological actions in tissues.

Although the role of ALS in the formation of ternary IGF complex has been extensively investigated in vitro, there are as yet few reported data on the in vivo effects of ALS. To investigate the biological effects of ALS in vivo we generated acid-labile subunit transgenic (TG) mice that overexpress ALS. To maximize our chances of observing phenotypic effects of ALS overexpression, the ubiquitous cytomegalovirus (CMV) promoter was used. This promoter results in high level expression in most tissues from early embryonic life. Here we report significant growth retardation and reduction in female fecundity in ALS TG mice.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Generation of TG mice
The ALS transgene was constructed using a 2000-bp EcoRI-EcoRI fragment of the human ALS cDNA containing the entire coding region of the cDNA (6). This fragment was inserted downstream of the 650-bp rabbit ß-globin intron and upstream of a fragment of the bovine GH gene containing the polyadenylation signal (9). The CMV promoter (10) was subcloned upstream of the rabbit ß-globin intron.

TG mice were generated by pronucleus injection of the linearized 3.8-kb transgene fragment, devoid of plasmid sequences, into fertilized CD-1 zygotes. The microinjected embryos were transferred into CD-1 foster mice using standard techniques (11). The founders, CMVALS-1, and CMVALS-2 were bred to homozygosity with wild-type CD-1 mice. CD-1 mice from the same colony, bred in a similar fashion, provided wild-type (Wt), non-TG control mice of the same genetic background. The ALS TG mice were also bred with phosphoglycerate kinase-binding protein-3 (PGKBP-3) TG mice previously generated in this laboratory (12). PGKBP-3 TG mice overexpress a human IGFBP-3 cDNA using the phosphoglycerate kinase promoter. The double TG mice express both the IGFBP-3 and ALS transgenes. All experiments were performed in accordance with protocols approved by the animal care committee of the Faculty of Medicine, University of Manitoba.

Southern blot analysis
The presence of the transgene was detected by Southern blot analysis of tail DNA. Filters were hybridized with the ALS fragment of the transgene under stringent conditions. For determination of transgene copy number, serial dilutions of tail DNA from homozygous TG mice were analyzed by dot-blot hybridization and quantified densitometrically. The data were compared to a standard curve of human ALS cDNA generated in a similar fashion.

RIAs
ALS and total plasma IGF-I was measured using human ALS ELISA and rat IGF-I RIA kits (Diagnostics Systems Laboratories, Inc., Webster, TX). GH was measured by RIA using a rat GH RIA kit (Amersham Pharmacia Biotech, Baie d’Urfé, Canada). Serum samples pooled from ALS TG mice were chromatographed on a Sephacryl S300 column as previously described (12). Fractions were collected and analyzed for ALS.

RNA extraction and ribonuclease protection assays (RPAs)
Total RNA was isolated from mouse liver using TRIzol reagent (Life Technologies, Inc., Burlington, Canada). RT-PCR was used to generate a mouse ALS cDNA fragment. First strand cDNA was synthesized from total RNA with AMV reverse transcriptase (Promega Corp., Madison, WI). PCR was used for the amplification of human ALS cDNA fragment. Amplification was performed in a thermocycler (Perkin-Elmer Corp., Norwalk, CT) under the following conditions: 95 C for 45 sec, 60 C for 30 sec, and 72 C for 90 sec for 30 cycles. The primers used for mouse ALS cDNA were 5'-CTGCTACTTACTGGCCTGGT-3' (sense) and 5'-TGCCCACCCTATTTAGGCC-3' (antisense). For human ALS cDNA the primers used were 5'-CAG CCC GCC CGA GGT CGT G-3' (sense) and 5'-ACC CCA TCA GGC CCT TGC GTC-3' (antisense). Fragments of the anticipated sizes (176 and 195 bp for mouse and human ALS cDNAs, respectively) were obtained.

The PCR products of mouse and human ALS were extracted from 1% agarose gel with the QIAquick gel extraction kit (QIAGEN, Mississauga, Canada) and cloned into the pCR II vector using reagent supplied by the manufacturer (Invitrogen, San Diego, CA). Bacterial colonies were selected with X-galactosidase plates. The sequence and orientation of the cDNA fragments were confirmed by DNA sequencing. The plasmids containing the mouse and human ALS cDNA fragments were linearized with XbaI and BamHI, respectively, for use as a template for RNA probe synthesis.

The in vitro transcription and labeling reaction was carried out using 80 µCi [32P]UTP (NEN Life Science Products, Boston, MA) and the Maxiscript SP6/T7 polymerase kit (Ambion, Inc., Austin, TX). A riboprobe for mouse cyclophilin (Ambion, Inc.) was used as the internal standard, and century RNA markers (Ambion, Inc.) were used as the molecular size indicators.

Total RNA was isolated with TRIzol reagent from 17-d-old fetal mice and from various tissues of 8-wk-old mice. A ribonuclease protection assay (RPA) kit (Ambion, Inc.) was used to quantify mouse ALS or human ALS mRNA abundance. Total RNA (20 µg) from mouse tissues was hybridized in hybridization buffer containing approximately 3 x 105 cpm 32P-labeled human or mouse ALS cRNA and cyclophilin cRNA by incubation overnight at 45 C. After hybridization, single stranded RNA was digested with ribonuclease A/T at 37 C for 30 min. The remaining RNA duplexes were separated on 5% polyacrylaminde/8 M urea gel. The hybridization signal was detected by autoradiography. The protected sizes for human ALS, mouse ALS, and mouse cyclophilin fragments were 195, 176, and 103 bp, respectively.

Western and ligand blotting
For immunodetection of human ALS, mouse embryos were homogenized in buffer [10 mm Tris-HCl (pH 8.0), 10 mM EDTA (pH 8.0), 0.15 M NaCl, 1% Nonidet P-40, 0.5% SDS, 1 µg/ml aprotinin, and 1 mM phenylmethylsulfonylfluoride]. The homogenate was clarified by centrifugation at 15,000 x g for 15 min at 4 C and separated by discontinuous 8% SDS-PAGE. The separated proteins were transferred onto nitrocellulose membrane (MSI, Westborough, MA) at 200 mA for 2 h. Serum samples (2 µl) from TG and Wt mice were analyzed on a 10% SDS-PAGE gel and transferred to nitrocellulose membrane. The blots were incubated overnight at 4 C with a 1:7,500 dilution of goat anti-ALS antibody (DSL-R00941, Diagnostics Systems Laboratories, Inc.). After washing with buffer [5 mM Tris-HCl (pH 7.4), 136 mM NaCl, and 0.05% Tween-20], the blots were incubated for 2 h at room temperature with horseradish peroxidase-conjugated donkey antigoat IgG (Promega Corp.) at a dilution of 1:5,000. Detection of immune complexes was achieved using an ECL Western blotting kit (Amersham Pharmacia Biotech).

For ligand blotting, the membrane was incubated with [125I]IGF-I, (500,000 cpm, NEN Life Science Products) at 4 C overnight. The membrane was subsequently washed four times with Tris-buffered saline, pH 7.6, and 0.1% Tween 20 and exposed to Kodak XAR film (Rochester, NY) at -70 C for 24–72 h.

Statistical analysis
Data are expressed as the mean ± SEM. Statistical differences between the growth curves for each group of mice were determined from an analysis of covariance with the repeated measure model using the SPSS for Windows software package (SPSS, Inc., Chicago, IL). A t test was used for single comparisons between TG and Wt mice. For determining statistical differences between multiple groups, an ANOVA, followed by Dunnett’s t test, were used.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The two founders were successfully bred to Wt CD1 mice to yield homozygous mice of the two strains, CMVALS-1 and CMVALS-2. The transgene copy numbers were 16 and 10 for CMVALS-1 and CMVALS-2, respectively. Figure 1Go shows the restriction endonuclease pattern obtained when DNA from each strain of TG mice was digested with SphI and BamHI endonucleases. The predominant band, 3.8 kb in size, resulted from multiple head to tail copies of the transgene. Less prominent bands of different sizes were apparent in the DNA from the two TG mouse strains, indicating different transgene insertion sites.



View larger version (60K):
[in this window]
[in a new window]
 
Figure 1. Southern blot of genomic DNA from homozygous CMVALS-1 and CMVALS-2 TG mice. Tail DNA (10 µg) was digested with each of the restriction endonucleases. ALS cDNA was used as a hybridization probe. The positions of the fragments where determined by comparison with DNA size markers.

 
ALS TG mice were phenotypically normal and fertile, and the female TG mice appeared to lactate normally. However, there was a significant reduction in litter size in both ALS TG mouse strains (Fig. 2Go). This reduction in litter size was a maternal, rather than fetal, effect, because a significant reduction in litter size was apparent when female TG mice were crossed with male Wt mice, but not when female Wt mice were crossed with male TG mice. Furthermore, the reduction in litter size was of the same magnitude in litters from female TG mice mated with Wt or TG mice.



View larger version (43K):
[in this window]
[in a new window]
 
Figure 2. Litter size in ALS TG mice. Male or female TG mice of CMVALS-1 and CMVALS-2 strains were mated with TG or Wt mice. The data are the mean ± SEM number of pups per litter for 4–14 litters/group. *, P < 0.05; **, P < 0.01; ***, P < 0.005 (differences between TG mice and the Wt control group).

 
Serum levels of human ALS were measured in 8-wk-old mice (Fig. 3Go). Using a human ELISA, most serum samples from Wt mice gave very low or undetectable levels of ALS, indicating minimal cross-reaction between mouse ALS and the antibody used in the ELISA assay. The levels of human ALS in the sera of TG mice ranged from 16–23 µg/ml. There were no significant differences in serum ALS levels between the two TG strains or between TG mice of different sexes. Sera from ALS TG mice were fractionated by gel chromatography. Two distinct immunoreactive peaks were identified (Fig. 4Go). The most prominent peak eluted at a position that corresponded to the elution position of alcohol dehydrogenase (mol wt, 150,000). A less prominent, more rapidly eluting peak was also observed and may represent an ALS dimer or ALS bound to other serum proteins.



View larger version (41K):
[in this window]
[in a new window]
 
Figure 3. Serum ALS levels in 8-wk-old Wt and TG mice determined using a human ALS ELISA assay. The data are the mean ± SEM for 4–17 mice/group. The asterisks indicate significance at the P < 0.001 level for differences between the TG mice and their sex-matched Wt control group. The lines indicate the difference between Wt and TG mice of different sexes.

 


View larger version (12K):
[in this window]
[in a new window]
 
Figure 4. Chromatographic analysis of serum from ALS TG mice. A serum sample from a TG mouse was fractionated on a Sephacryl S300 column. Human ALS present in the fractions was determined by ELISA. The arrow indicates the position of elution of alcohol dehydrogenase.

 
Sera from 2-month-old homozygous TG and Wt mice were also analyzed by Western blotting (Fig. 5Go). Immunoreactive human ALS was detected in the TG mice. When the autoradiographs were analyzed by densitometry, there was no significant difference in the abundance of human ALS as detected by Western blotting between CMVALS-1 and CMVALS-2 mice.



View larger version (8K):
[in this window]
[in a new window]
 
Figure 5. Western blot analysis of serum samples from TG and Wt mice. Serum samples (2.5 µl) from male and female CMVALS-1 TG and Wt mice were resolved on an 8% SDS-PAGE gel and analyzed by Western blotting. The arrows indicate the position of the protein mol wt markers. Similar data were obtained when sera from CMVALS-2 TG mice were analyzed.

 
Ligand blotting was used to examine the abundance of IGFBPs in ALS TG mice (Fig. 6Go). Three bands were identified in each of the serum samples. The largest and most abundant of these was presumed to represent IGFBP-3. Additional bands with apparent sizes of 30 and 20 kDa were also recognized. These were presumptively identified as IGFBP-2 and IGFBP-4. When quantified by densitometry there were no significant differences between CMVALS-1 and CMVALS-2 TG mice or between TG mice and Wt mice in the abundance of any of these IGFBPs.



View larger version (58K):
[in this window]
[in a new window]
 
Figure 6. Ligand blot analysis of serum samples from TG and Wt mice. Serum samples (2.5 µl) from male and female Wt and CMVALS-1 TG mice were resolved on a 10% SDS-PAGE gel and analyzed by ligand blotting using [125I]IGF-I as a probe. The arrows indicate the position of the protein mol wt markers. Similar data were obtained when sera from CMVALS-2 TG mice were analyzed.

 
Total serum IGF-I was measured in serum from 2-month-old male TG and Wt mice. IGF-I levels were 541.9 ± 52.5 and 509 ± 35.7 ng/ml for CMVALS-1 and CMVALS-2, respectively. These levels did not differ significantly from the levels in age-matched Wt mice (545.8 ± 38.8 ng/ml). Similarly, there was no significant difference in GH levels in plasma samples from overnight fasted TG or Wt male mice (1.89 ± 0.56, 2.29 ± 0.61, and 2.79 ± 0.80 ng/ml for CMVALS-1, CMVALS-2, and Wt mice, respectively).

A human ALS mRNA-specific RPA was used to assess the expression of the transgene products. Using this assay, transgene expression was easily detected in RNA extracted from 17-d-old embryos (data not shown). A careful analysis of tissue transgene expression was undertaken in 2-month-old mice (Fig. 7AGo). Using a human ALS mRNA-specific RPA, expression of the transgene was detected in the liver, kidney, lungs, heart, brain, and spleen. The highest level was detectable in the heart, and the lowest level was present in the spleen. Using a mouse ALS mRNA-specific RPA, expression of the mouse ALS gene was detectable only in the liver (Fig. 7BGo). There was no significant difference in the level of endogenous mouse ALS expression in TG and Wt mice (Fig. 7CGo).



View larger version (82K):
[in this window]
[in a new window]
 
Figure 7. Tissue distribution of transgene mRNA expression. RNA was extracted from various tissues of 8-wk-old CMVALS-1 TG mice and analyzed using species-specific RPA assays for ALS. Cyclophilin mRNA was also measured as an internal control. A, Expression of human ALS mRNA; B and C, expression of mouse ALS mRNA. C, RNA from five individual liver samples from TG and Wt mice were analyzed. Similar data were obtained with TG mice of the CMVALS-2 strain.

 
The birth weight of CMVALS-1 or CMVALS-2 TG mice did not differ significantly from that of Wt mice. The birth weights were 1.577 ± 0.019, 1.551 ± 0.020, and 1.577 ± 0.012 g for male Wt, CMVALS-1, and CMVALS-2 mice, respectively, and 1.516 ± 0.024, 1.518 ± 0.019, and 1.491 ± 0.016 for female Wt, CMVALS-1, and CMVALS-2 mice, respectively. In addition, nose to tail length was not significantly different in the 3-month-old TG mice compared with the WT mice (data not shown). The postnatal growth curves for ALS TG mice and Wt mice were compared over the first 3 months of age (Fig. 8Go). A modest reduction in postnatal body weight gain was observed in both CMVALS-1 and CMVALS-2 mice. Using analysis of covariance with repeated measures, there was a significant difference in the growth curves for the ALS TG mice compared with Wt mice (P = 0.045, P = 0.001, P = 0.05, and P = 0.001 for CMVALS-1 males, CMVALS-2 males, CMVALS-1 females, and CMVALS-2 female mice, respectively). Over the first 3 months of life, the average body weight of TG mice was significantly reduced by 4.2–8.1% compared with that of Wt mice. The difference between ALS TG mice and Wt mice was particularly apparent during the first 3 wk of life, when body weight was reduced by 9–17% of that of Wt mice (Fig. 8Go). CMVALS-2 TG mice demonstrated a more marked reduction in body weight than CMVALS-1 TG mice.



View larger version (23K):
[in this window]
[in a new window]
 
Figure 8. Body weight gain in Wt and ALS TG mice. The change in body weight with age in Wt and TG mice is shown for male and female mice. The data are the mean of 19–30 mice/group. Error bars (~3% of the mean) have been deleted for clarity. The statistical differences between the entire growth curves for TG and Wt mice were determined by analysis of covariance with repeated measures, followed by Dunnett’s t test. The inset shows the mean percent reduction in body weight of TG mice compared with Wt mice.

 
Organ allometry was examined in 12-wk-old mice. There were no consistent differences in relative weights of the major organs between ALS TG mice and Wt mice, indicating a proportionate reduction in organ weight to match the reduction in body weight seen in TG mice (Table 1Go). The relative weight of the testes was significantly increased in CMVASL-2 TG mice compared with Wt mice, but this increase in relative weight was not observed in CMVALS-1 TG mice.


View this table:
[in this window]
[in a new window]
 
Table 1. Organ allometry in ALS transgenic mice

 
We previously reported the characterization of TG mice that overexpress human IGFBP-3 under the PGK promoter (12). PGKBP-3 TG mice exhibit a significant attenuation in prenatal and early postnatal growth. To determine the effects of ALS overexpression in TG mice that overexpress IGFBP-3, double transgenic mice were generated by breeding ALS TG mice with PGKBP-3 TG mice. The growth effects of overexpression of ALS and IGFBP-3 were additive. At 1 month of age both PGKBP-3 and ALS TG mice weighed significantly less than Wt mice (Fig. 9Go). PGKBP-3/CMVALS-1 and PGKBP-3/CMVALS-2 double TG mice weighed significantly less than CMVALS-1 and CMVALS-2 TG mice, respectively. PGKBP-3 TG mice weighed significantly less than CMVALS-2 and CMVALS-2 TG mice. However, the PGKBP-3/CMVALS-1 double TG mice were significantly lighter than the PGKBP-3 mice. A similar trend was observed for PGKBP-3/CMVALS-2 double transgenic mice; however, the difference between these double TG animals and PGKBP-3 TG mice did not achieve significance. Similar data were obtained when the mice were analyzed at 3 months of age (data not shown).



View larger version (18K):
[in this window]
[in a new window]
 
Figure 9. Body weight in TG mice and double TG mice that overexpress both IGFBP-3 and ALS. The absolute body weight was expressed as a percentage of the mean for the sex- and age-matched Wt mice. The data are the mean ± SEM. The number of mice per group is indicated. The statistical differences between the groups of mice were determined using ANOVA and Dunnett’s t test. *, P < 0.01; **, P < 0.001 (difference from the Wt controls). The differences among the various groups are indicated on the graph.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
In plasma the majority of IGF-I or IGF-II is present as a ternary complex composed of IGFBP-3 and ALS (1). The ternary complex is not detectable in the circulation before birth or during the early postnatal period when most of the IGF is present bound to other IGFBPs as a binary complex (13). Under the influence of GH, hepatic expression of ALS and IGFBP-3 was enhanced, and the abundance of the ternary complex increased dramatically in first few weeks of rodent life (14, 15, 16). Unlike the binary complex, which can transverse the capillary endothelial barrier, the ternary complex is thought to be confined to the circulation (1, 8).

Although some ALS is present at birth in the rodent and is functionally capable of interacting with the IGFBP-3/IGF binary complex, the concentration appears to be insufficient to lead to the generation of ternary complex (13). The enhanced expression of ALS, with an eventual 2- to 3-fold molar excess over IGFBP-3 (13, 14), results in the gradual appearance of the ternary complex in the circulation in the first few weeks of postnatal life. This change in the compartmentalization of IGF in the circulation is thought to limit the mitogenic and hypoglycemic actions of IGF-I and IGF-II in the first few weeks of life (1, 17). In the rodent, IGF-II declines in importance during this period because of developmental down-regulation of expression (18), and IGF-I becomes the most abundant IGF in adult life. The appearance of the ternary complex during the early postnatal period may serve as a circulating reservoir of IGF-I. The functional significance of this reservoir has been called into question in recent times with the demonstration that normal postnatal growth can occur in mice with conditional nullification of hepatic IGF-I expression (19, 20). These mice have low circulating total IGF-I levels, although free IGF-I levels may be normal.

To date there are no reported data on the in vivo effects of ALS on growth or other parameters. To investigate the biological effects of chronic elevated ALS levels in vivo, we generated TG mice that overexpress ALS. Here we report the characterization of transgenic mice in which ALS is expressed at high levels from very early in embryonic life. The CMV promoter is known to be transcriptionally active in mouse embryos (10, 21), and human ALS mRNA was easily demonstrable in 17-d-old embryos. High levels of human ALS were observed in the circulation of both TG strains. In addition, transgene-derived ALS mRNA expression was abundant in most tissues examined in TG mice, indicating that the potential exists for the formation of ternary complex in the extravascular space.

Although the actual serum levels of endogenous ALS in the mouse circulation are not known, the level in the adult rat is approximately 40 µg/ml (14, 15). In ALS TG mice, the measured level of human ALS was about 20 µg/ml. As the transgene was transcriptionally active early in embryogenesis, similar circulating human ALS levels were probably present throughout fetal life, when endogenous ALS levels are low in humans and rodents (1, 15). Despite this increase in circulating ALS and the expression during early embryonic life, the ALS TG mice were phenotypically normal at birth, and only a modest effect on postnatal growth was observed.

Estimation of the serum levels of IGFBP-3 from ligand blots indicated that the circulating IGFBP-3 concentration was not increased in TG mice compared with Wt mice. Similarly, serum IGF-I levels were not elevated in ALS TG mice. Thus, it would appear that enhanced expression of ALS does not result in a compensatory increase in IGFBP-3 and IGF-I levels or increased amounts of ternary complex. The absence of an effect on IGFBP-3 and IGF-I levels is not attributable to the inability of human transgene-derived ALS to form a ternary complex with mouse IGFBP-3, as chromatography and SDS-PAGE demonstrated that the majority of the human ALS was present as a 150-kDa complex. Although ALS expression and secretion are tightly regulated by GH, with cortisol and insulin also having an effect (15, 16), the actual levels of ALS surprisingly do not appear to be rate limiting in the formation of ternary complexes in perinatal life (13) or GH deficiency (22). Rather, ternary complex formation appears to be limited by the availability of IGF-I (22). Thus, excess ALS in the circulation of TG mice would be unlikely to have any major effect on ternary complex formation.

The failure to perturb the circulating IGF system may account for the relatively modest growth retardation observed in the ALS TG mice. A small, but significant, reduction in body weight gain was observed in both strains of ALS TG mice. This was most apparent in the first 4 wk, when growth velocity, as measured by weight gain, is at its maximum.

Under normal circumstances, the expression of ALS is tightly restricted to the liver (15), with smaller amounts of expression detected by in situ hybridization in the kidney cortex, bone, and ovarian tissue (23, 24). In ALS TG mice, tissue expression of the transgene was ubiquitous, raising the possibility that the local tissue IGF system could be perturbed in these mice. Recent reports of normal growth after selective disruption of hepatic IGF-I expression has suggested that paracrine/autocrine IGF-I may be more important than circulating IGF-I in normal growth (19, 20). In contrast, Ueki et al. (17) recently reported modest postnatal growth retardation in ALS null mutant mice. These ALS knockout mice had reduced circulating levels of IGFBP-3 and IGF-I (17), suggesting that the circulating ternary complex may indeed have some role in postnatal growth. Interestingly, as in the overexpressing ALS TG mice reported here, birth weight was normal in the ALS knockout mice.

High levels of tissue expression of ALS could potentially perturb paracrine IGF-I action if indeed IGF-I present in the ternary complex is functionally inactive. However, to our knowledge there are no published data that directly addresses this question. Indeed, IGF-I complexed to IGFBP-3 appears to be more potent than free IGF-I under many conditions (25, 26, 27, 28). ALS may simply limit the biological activity of circulating IGF-I by confining it to the intravascular space rather than inhibiting IGF-I interaction with its receptor. Careful allometry failed to demonstrate any consistent significant differences in organ weight between ALS TG and Wt mice. Of note is the fact that the brain, a tissue particularly sensitive to IGF-I levels (29, 30), was of normal size in ALS TG mice. ALS is not normally expressed in the brain (31). The normal brain size in ALS TG mice would suggest that tissue ALS overexpression does not impede the paracrine actions of IGF-I, at least in this organ. A possible explanation for this lack of effect of ALS may be the fact that IGFBP-3 and -5, the two binding proteins that can interact with ALS, are expressed in the brain at a relatively late stage in embryogenesis (32, 33).

A consistent abnormality in ALS TG was a significant reduction in litter size. IGF-I has a crucial role in ovarian follicular development. Expression of IGF-I increases in the growing follicle in the mouse (34). Similarly, IGFBP-5, which is capable of binding to ALS, is important in the survival of slow-growing and immature preantral follicles (34). There are no data for ALS expression in mouse ovarian tissue. However, in the porcine ovary ALS is present in follicular fluid and is expressed in both thecal and granulosa cells in a similar pattern as IGFBP-3 during follicular development (24). A significant reduction in litter size was observed in both ALS TG mouse strains. This effect was a maternal effect, rather than an effect of ALS expression in the developing embryo, as it was observed both in litters where all pups were TG and in mixed litters derived from mating TG females with Wt males. In contrast, no reduction in litter size was apparent when TG male mice were mated with Wt females. A similar reduction in litter size has been reported in TG mice that overexpress IGFBP-1 in the ovary, and in this case the reduction in litter size was attributable to a decrease in the number of ovulatory follicles (35). Decreased litter size was also observed in IGFBP-3 TG mice (12). Thus, it would appear that litter size might be a very sensitive marker of perturbations in the ovarian IGF system.

Although overexpression of ALS had only a modest growth effect, the combination of both ALS and IGFBP-3 overexpression resulted in a more marked reduction in body weight than overexpression of either IGFBP-3 or ALS alone. Usually there is a molar excess of ALS to IGFBP-3 in serum (1). However, in IGFBP-3 TG animals there may be insufficient endogenous ALS to allow for the full growth-attenuating effect of IGFBP-3 overexpression to be observed. In the double TG mice the increased levels of ALS together with overexpressed IGFBP-3 may allow for a larger pool of ternary complex and for the full manifestation of the effect of excess IGFBP-3.

In summary, overexpression of ALS in transgenic mice has no significant effect on the levels of major components of the circulating endocrine IGF system, but has a modest effect on growth and reproduction. Furthermore, overexpression of ALS appears to modulate the effects of concomitantly overexpressed IGFBP-3.


    Acknowledgments
 
The authors thank Zengdun Shi for his assistance in performing the ligand blot experiment.


    Footnotes
 
This work was supported by grants from the Canadian Institutes of Health Research (to L.J.M.) and NIH Grant R01-DK-38773 (to D.R.P.).

1 Present address: Animal Health Discovery Research, Pharmacia, Kalamazoo, Michigan 49007-4940. Back

2 Recipient of a Medical Research Council Senior Scientist award and an endowed Research Professorship in Metabolic Diseases. Back

Abbreviations: ALS, Acid-labile subunit; CMV, cytomegalovirus; IGFBP, IGF-binding protein; PGK, phosphoglycerate kinase; PGKBP, phosphoglycerate kinase-binding protein; RPA, ribonuclease protection assay; TG, transgenic; Wt, wild-type.

Received May 14, 2001.

Accepted for publication June 18, 2001.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Baxter RC 1994 Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res 42:140–144[Medline]
  2. Campbell PG, Durham SK, Hayes JD, Suwanichkul A, Powell DR 1999 Insulin-like growth factor-binding protein-3 binds fibrinogen and fibrin. J Biol Chem 42:30215–30221
  3. Campbell PG, Durham SK, Suwanichkul A, Hayes JD, Powell DR 1998 Plasminogen binds the heparin-binding domain of insulin-like growth factor-binding protein-3. Am J Physiol 275:E321–E331
  4. Shi Z, Xu W, Loechel F, Wewer UM, Murphy LJ 2000 ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor binding protein-3. J Biol Chem 275:18574–18580[Abstract/Free Full Text]
  5. Twigg SM, Kiefer MC, Zapf J, Baxter RC 1998 Insulin-like growth factor binding protein 5 complexes with the acid-labile subunit. Role of the carboxyl-terminal domain. J Biol Chem 273:28791–28798[Abstract/Free Full Text]
  6. Leong SR, Baxter RC, Camerato T, Dai J, Wood WI 1992 Structure and functional expression of the acid-labile subunit of the insulin-like growth factor binding protein complex. Mol Endocrinol 19:267–277
  7. Lee CY, Rechler MM 1995 Purified rat acid-labile subunit and recombinant human insulin-like growth factor (IGF)-binding protein-3 can form a 150-kilodalton binary complex in vitro in the absence of IGFs. Endocrinology 136:4982–4989[Abstract]
  8. Binoux M, Hossenlopp P 1988 Insulin-like growth factor (IGF) and IGF-binding proteins: Comparison of human serum and lymph. J Clin Endocrinol Metab 134:2404–2409
  9. Yew NS, Wysokenski DM, Wang KX, et al. 1997 Optimization of plasmid vectors for high-level expression in lung epithelial cells. Hum Gene Ther 8:575–584[Medline]
  10. Baskar JF, Smith PP Nilaver G, et al. 1996 The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell typespecific expression in transgenic mice. J Virol 70:3207–3214[Abstract]
  11. Hogan B, Costantini F, Lacy E 1986 Manipulating the mouse embryo, a laboratory manual. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 152–203
  12. Modric T, Silha J, Shi Z, et al. 2001 Phenotypic manifestations of insulin-like growth factor binding protein-3 overexpression in transgenic mice. Endocrinology 142:1958–1967[Abstract/Free Full Text]
  13. Lee CY, Cohen FJ, Wu HB, Ooi GT, Rechler MM 1999 The absence of 150-kDa insulin-like growth factor complexes in fetal rat serum is not due to a lack of functional acid-labile subunit. Horm Metab Res 31:182–185[Medline]
  14. Baxter RC, Dai J 1994 Purification and characterization of the acid-labile subunit of rat serum insulin-like growth factor binding protein complex. Endocrinology 134:848–852[Abstract/Free Full Text]
  15. Dai J, Baxter RC 1994 Regulation in vivo of the acid-labile subunit of rat serum insulin-like growth factor binding protein complex. Endocrinology 135:2335–2341[Abstract]
  16. Ooi GT, Cohen FJ, Tseng LY, Rechler MM, Boisclair YR 1997 Growth hormone stimulates transcription of the gene encoding the acid-labile subunit (ALS) of the circulating insulin-like growth factor-binding protein complex and ALS promoter activity in rat liver. Mol Endocrinol 11:997–1007[Abstract/Free Full Text]
  17. Ueki I, Ooi GT, Tremblay ML, Hurst KR, Bach LA, Boisclair YR 2000 Inactivation of the acid labile subunit in mice results in mild retardation of postnatal growth despite profound disruptions in the circulating insulin-like growth factor system. Proc Natl Acad Sci USA 97:6868–6873[Abstract/Free Full Text]
  18. Brown AL, Graham DE, Nissley SP, Hill DJ, Strain AJ, Rechler MM 1986 Developmental regulation of insulin-like growth factor-II mRNA in different rat tissues. J Biol Chem 261:13144–13151[Abstract/Free Full Text]
  19. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D 1999 Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 96:7324–7329[Abstract/Free Full Text]
  20. Sjogren K, Liu JL, Blad K, et al. 1999 Liver-derived insulin-like growth factor-I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 96:7088–7092[Abstract/Free Full Text]
  21. Furth PA, Hennighausen L, Baker C, Beatty B, Woychick R 1991 The variability in activity of the universally expressed human cytomegalovirus major immediate early gene 1 enhancer/promoter in transgenic mice. Nucleic Acids Res 19:6205–6208[Abstract/Free Full Text]
  22. Lewitt MS, Saunders H, Phuyal JL, Baxter RC 1994 Complex formation by human insulin-like growth factor-binding protein-3 and human acid-labile subunit in growth hormone-deficient rats. Endocrinology 134:760–768[Abstract/Free Full Text]
  23. Chin E, Zhou J, Dai J, Baxter RC, Bondy CA 1994 Cellular localization and regulation of gene expression for components of the insulin-like growth factor ternary binding protein complex. Endocrinology 134:2498–2504[Abstract/Free Full Text]
  24. Wandji SA, Gadsby JE, Simmen FA, Barber JA, Hammond JM 2000 Porcine ovarian cells express messenger ribonucleic acids for the acid-labile subunit and insulin-like growth factor binding protein-3 during follicular and luteal phases of the estrous cycle. Endocrinology 141:2638–2647[Abstract/Free Full Text]
  25. DeMellow JSM, Baxter RC 1988 Growth hormone dependent insulin like growth factor (IGF) binding protein both inhibits and potentiates IGF-I stimulated DNA synthesis in human fibroblasts. Biochem Biophys Res Commun 156:199–204[CrossRef][Medline]
  26. Conover CA, Bale LK, Durham SK, Powell DR 2000 Insulin-like growth factor (IGF) binding protein-3 potentiation of IGF-I action is mediated through the phosphatidylinositol-3-kinase pathway and is associated with alteration in protein kinase B/AKT sensitivity. Endocrinology 141:3098–3103[Abstract/Free Full Text]
  27. Blum WF, Jenne EW, Reppin JF, Kietzmann IT, Ranke MB, Bierch JR 1989 Insulin-like growth factor I (IGF-I)-binding protein complex is a better mitogen than free IGF-I. Endocrinology 125:766–772[Abstract/Free Full Text]
  28. Ramagnolo D, Akers RM, Byatt JC, Wong EA, Turner JD 1994 IGF-I induced IGFBP-3 potentiates the mitogenic actions of IGF-I in mammary epithelial MD-IGF-I cells. Mol Cell Endocrinol 102:133–139
  29. Ye P, Carson J, D’Ercole AJ 1995 In vivo actions of insulin-like growth factors (IGF-I) on brain myelination: studies of IGF-I and IGF binding protein-1 (IGFBP-1) transgenic mice. J Neurosci 15:7344–7356[Abstract]
  30. Ni W, Rajkumar K, Nagy J, Murphy LH 1997 Impaired brain development and reduced reactive astrocyte response to injury in insulin-like growth factor binding protein-1 transgenic mice. Brain Res 769:97–107[CrossRef][Medline]
  31. Mewar R, McMorris FA 1997 Expression of insulin-like growth factor-binding protein messenger RNAs in developing rat oligodendrocytes and astrocytes. J Neurosci Res 50:721–728[CrossRef][Medline]
  32. Green BN, Jones SB, Streck RD, Wood TL, Rotwein P, Pintar JE 1994 Distinct expression patterns of insulin-like growth factor binding protein 2 and 5 during fetal and postnatal development. Endocrinology 134:954–962[Abstract/Free Full Text]
  33. Cheng HL, Sullivan KA, Feldman EL 1996 Immunohistochemical localization of insulin-like growth factor binding protein-5 in the developing rat nervous system. Brain Res Dev Brain Res 92:211–218[CrossRef][Medline]
  34. Wandji SA, Wood TL, Crawford J, Levison SW, Hammond JM 1998 Expression of mouse ovarian insulin-like growth factor components during follicular development and atresia. Endocrinology 139:5205–5214[Abstract/Free Full Text]
  35. Kadaba R, Barron D, Lewitt MS, Murphy LJ 1995 Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice. Endocrinology 136:4029–4034[Abstract]



This article has been cited by other articles:


Home page
FASEB J.Home page
S. Yakar, C. J. Rosen, M. L. Bouxsein, H. Sun, W. Mejia, Y. Kawashima, Y. Wu, K. Emerton, V. Williams, K. Jepsen, et al.
Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism
FASEB J, March 1, 2009; 23(3): 709 - 719.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. Zhang, S. Patil, B. Chauhan, S. Guo, D. R. Powell, J. Le, A. Klotsas, R. Matika, X. Xiao, R. Franks, et al.
FoxO1 Regulates Multiple Metabolic Pathways in the Liver: EFFECTS ON GLUCONEOGENIC, GLYCOLYTIC, AND LIPOGENIC GENE EXPRESSION
J. Biol. Chem., April 14, 2006; 281(15): 10105 - 10117.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, and C. Y. Bowers
Somatotropic and Gonadotropic Axes Linkages in Infancy, Childhood, and the Puberty-Adult Transition
Endocr. Rev., April 1, 2006; 27(2): 101 - 140.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
P. Froment, C. Staub, S. Hembert, C. Pisselet, M. Magistrini, B. Delaleu, D. Seurin, J. E. Levine, L. Johnson, M. Binoux, et al.
Reproductive Abnormalities in Human Insulin-Like Growth Factor-Binding Protein-1 Transgenic Male Mice
Endocrinology, April 1, 2004; 145(4): 2080 - 2091.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. V. Silha and L. J. Murphy
Minireview: Insights from Insulin-Like Growth Factor Binding Protein Transgenic Mice
Endocrinology, October 1, 2002; 143(10): 3711 - 3714.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Silha, J. V.
Right arrow Articles by Murphy, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Silha, J. V.
Right arrow Articles by Murphy, L. J.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals